Simvastatin

Publication Title: 
Postgraduate Medicine

Advances in treatment of elevated cholesterol levels and recent documentation of efficacy and safety in clinical trials justify expanded use of cholesterol-lowering therapy in clinical practice. Patients with CHD or other forms of clinical atherosclerotic disease can benefit from aggressive cholesterol management. Maximal dietary modification, weight control, and physical activity are valuable adjuncts to drug therapy in secondary prevention. Recent studies have shown that appropriate use of cholesterol-lowering drugs is cost-effective and efficacious in patients with CHD.

Author(s): 
Grundy, S. M.
Publication Title: 
Hematology/Oncology Clinics of North America

Statin drugs and various isoprenoids from plant origins inhibit mevalonic acids, cholesterol, and other isoprenoid products. Among these, reduction of farnesyl and geranylgeranyl prenylated proteins impedes signal transduction at the cellular level. The authors envision that limiting such prenylated proteins downregulates thrombin-stimulated events, including decreasing the expression and availability of protease-activated receptor-1 mitigating thrombin stimulation of cells, tissue factor preventing additional thrombin generation, and plasminogen activator inhibitor-1 allowing thrombosis.

Author(s): 
Fenton, J. W.
Shen, G. X.
Minnear, F. L.
Brezniak, D. V.
Jeske, W. P.
Walenga, J. M.
Bognacki, J. J.
Ofosu, F. A.
Hassouna, H. I.
Publication Title: 
Molecular Pharmacology

Doxorubicin efficacy in cancer therapy is hampered by the dose-dependent side effects, which may be overcome by reducing the drug's dose and increasing its efficacy. In the present work, we suggest that the activation of the nuclear factor-kappaB (NF-kappaB) pathway and of nitric-oxide (NO) synthase increases the doxorubicin efficacy in human colon cancer HT29 cells.

Author(s): 
Riganti, Chiara
Doublier, Sophie
Costamagna, Costanzo
Aldieri, Elisabetta
Pescarmona, Gianpiero
Ghigo, Dario
Bosia, Amalia
Publication Title: 
Physiology & Behavior

Ayurveda means "the science of life". Ayur means "life" and Veda means "knowledge or science". It is the oldest medical system in the world. Its origins can be traced as far back as 4500 BC, to four ancient books of knowledge, (the "Vedas") and it is still officially recognized by the government of India. The present study was aimed at investigating the effects of Anwala churna (Emblica officinalis Gaertn.), an Ayurvedic preparation on memory, total serum cholesterol levels and brain cholinesterase activity in mice.

Author(s): 
Vasudevan, Mani
Parle, Milind
Publication Title: 
Circulation

BACKGROUND: Prospective studies indicate that baseline levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. Limited studies have examined therapies that influence high-sensitive CRP (hs-CRP) levels, especially in hyperlipidemic patients.

Author(s): 
Jialal, I.
Stein, D.
Balis, D.
Grundy, S. M.
Adams-Huet, B.
Devaraj, S.
Publication Title: 
Arteriosclerosis, Thrombosis, and Vascular Biology

Clinical trials with statins have demonstrated significant reductions in cardiovascular events. Remnant lipoproteins are independent predictors of cardiovascular events. Because of the paucity of data on the effect of statins on remnant lipoproteins, we tested the effect of pravastatin, simvastatin, and atorvastatin on remnant lipoprotein cholesterol (RLP-C) levels in a randomized crossover study in patients with combined hyperlipidemia.

Author(s): 
Stein, D. T.
Devaraj, S.
Balis, D.
Adams-Huet, B.
Jialal, I.
Publication Title: 
The Journal of Clinical Endocrinology and Metabolism

CONTEXT: Cardiovascular disease is a major cause of mortality in type 1 diabetes (TIDM). TIDM is a proinflammatory state. Whereas there is consensus on lipid management in type 2 diabetes, there is a lack of data in type 1 diabetes. In addition to benefits on the lipid profile, statin therapy is antiinflammatory. OBJECTIVE: There are scant data on statin therapy in T1DM. Thus, we tested the effect of simvastatin, compared with placebo, on biomarkers of inflammation and monocyte function in TIDM patients.

Author(s): 
Jialal, Ishwarlal
Miguelino, Eric
Griffen, Steven C.
Devaraj, Sridevi
Publication Title: 
The American Journal of Cardiology

The metabolic syndrome (MS) is characterized by low-grade inflammation and confers an increased risk for diabetes mellitus and cardiovascular disease. Statins reduce cardiovascular events in patients with the MS and have pleiotropic effects in addition to lowering low-density lipoprotein cholesterol.

Author(s): 
Devaraj, Sridevi
Siegel, David
Jialal, Ishwarlal
Publication Title: 
Diabetes Care

OBJECTIVE: We hypothesized that simvastatin may reduce adiponectin levels and insulin sensitivity in hypercholesterolemic patients. RESEARCH DESIGN AND METHODS: This was a randomized, double-blind, placebo-controlled, parallel study. Age, sex, and BMI were matched. Thirty-two patients were given placebo, and 30, 32, 31, and 31 patients were given daily 10, 20, 40, and 80 mg simvastatin, respectively, during a 2-month treatment period.

Author(s): 
Koh, Kwang Kon
Quon, Michael J.
Han, Seung Hwan
Lee, Yonghee
Ahn, Jeong Yeal
Kim, Soo Jin
Koh, Yesl
Shin, Eak Kyun
Publication Title: 
Metabolic Syndrome and Related Disorders

BACKGROUND: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS.

Author(s): 
Wang, Long
Rockwood, Jason
Zak, Danielle
Devaraj, Sridevi
Jialal, Ishwarlal

Pages

Subscribe to RSS - Simvastatin